Competitor Landscape: Inflammatory Bowel Disease (IBD)
Powered by
All the vital news, analysis, and commentary curated by our industry experts.
Executive Summary: Contains analysis of key market events that have occurred during the previous month and which have impacted Sociable Pharma’s view of the disease landscape
Landscape Updates: ‘Order of Entry’ analysis, detailing timeline forecasts for each drug in Phase II development or higher; Timeline forecasts for each approved product’s lifecycle management initiatives; ‘Market Entry’ & ‘Direction of Travel’ positioning analysis for pipeline & currently approved therapies
Pipeline Landscape: An overview of pipeline candidates, containing snapshots of current development status; Expected drug-specific events & milestones until YE 2019
Approved Product Landscape: An overview of pipeline candidates, containing snapshots of current development status; Expected drug-specific events & milestones until YE 2019
Scope
The briefing is based on Sociable Pharma’s analysis of clinical trial data from company announcements (press releases, earnings calls) and clinical trial databases (clinicaltrials.gov)
Sociable Pharma applies disease & drug specific assumptions in order to forecast US & EU approvals for drugs in Phase II development, or higher – these are outlined in the report Appendix
Forecasts are presented in pipeline forecast figures & detailed tables
‘Market Entry’ & ‘Direction of Travel’ positioning analysis for pipeline & currently approved therapies is also provided
Key Highlights
Given the significant time difference between primary completion dates of VISIBLE 1 (UC) and VISIBLE 2 (Crohn’s disease), Takeda will likely file the subQ formulation of VDZ in UC before filing in Crohn’s disease, in order to mitigate against the risk of ustekinumab becoming established in UC
RHB-104 will likely be the first antibiotic approved in Crohn’s disease, but RedHill BioPharma announced in the results webcast that it will likely need to conduct an additional Phase III trial to support a New Drug Application (NDA) in the US, which will delay its approval timeline
Allergan is the second company, after Genentech (with UTTR1147A), to use vedolizumab as an active comparator in a Phase II UC trial, with the design suggesting brazikumab could proceed directly to Phase III if it is successful at Phase II
Reasons to Buy
Provides details on forecast US & EU approvals for pipeline drugs in Phase II development or higher
Includes potential positioning strategies that companies may adopt for their novel assets once they are approved & launched in the market
Reviews ongoing lifecycle management strategies for existing players in the market
A detailed methodology allows you to understand the forecast assumptions made, enabling cross comparison with your own internal forecasts
Table of Contents
Frequently asked questions
Get in touch to find out about multi-purchase discounts
reportstore@globaldata.com
Tel +44 20 7947 2745
Every customer’s requirement is unique. With over 220,000 construction projects tracked, we can create a tailored dataset for you based on the types of projects you are looking for. Please get in touch with your specific requirements and we can send you a quote.